Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis

Modern Rheumatology

Volumn 29, Issue 1, 2019, Pages 31-40

  Kameda, Hideto ^a   Fujii, Takao ^b   Nakajima, Ayako ^c   Koike, Ryuji ^d   Sagawa, Akira ^e   Kanbe, Katsuaki ^f   Tomita, Tetsuya ^g   Harigai, Masayoshi ^h   Suzuki, Yasuo ⁱ  

^a TOHO UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^e Sagawa Akira Rheumatology Clinic   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g OSAKA UNIVERSITY   (Japan)

^h TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁱ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Guideline; Japan College of Rheumatology; methotrexate; rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AUROTHIOMALATE; BUCILLAMINE; CYCLOSPORINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TACROLIMUS; ANTIRHEUMATIC AGENT;

ANTIVIRAL THERAPY; APLASTIC ANEMIA; ARTICLE; DIFFUSE LARGE B CELL LYMPHOMA; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DISEASE; LACTATION; LEUKOPENIA; LIVER DISEASE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MYELODYSPLASTIC SYNDROME; PANCYTOPENIA; PERIOPERATIVE PERIOD; PNEUMOCYSTIS PNEUMONIA; PREGNANCY; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; DOSE RESPONSE; FEMALE; JAPAN; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PROCEDURES; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; MIDDLE AGED; PNEUMONIA, PNEUMOCYSTIS; RISK ADJUSTMENT; TREATMENT OUTCOME;

EID: 85047359016     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2018.1472358     Document Type: Article

References (111)

1. Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3–15.
2. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509.
3. Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis. 2014;73:536–43.
4. Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, et al. The first double-blind, randomized, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor-prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016;75:75–83.
5. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.
6. Claudepierre P, Urien S, Chevalier X, Chassany O, Larget-Piet B, Tillement JP., Methotrexate serum binding in rheumatoid arthritis. Int J Clin Pharmacol Ther. 1994;32:113–15.
7. Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44(S1):1–58.
8. Pavy S, Constantin A, Pham T, Gosseec L, Maillefert JF, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73:388–95.
9. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086–93.
10. Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis. Jpn J Inflammat. 1996;16:437–58.
11. Visser K, van der Heijde D., Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68:1094–9.
12. Mouterde G, Baillet A, Gaujoux-Viala C, Cantagrel A, Wendling D, Le Loët X, et al. Optimizing methotrexate therapy in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. 2011;78:587–92.
13. Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS., A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol. 1984;11:760–3.
14. Hobl EL, Mader RM, Jilma B, Duhm B, Mustak M, Bröll H, et al. A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis. Clin Ther. 2012;34:1195–203.
15. Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomized, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74:19–26.
16. Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75:1081–91.
17. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542–50.
18. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–9.
19. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443–9.
20. Seideman P. Methotrexate-the relationship between dose and clinical effect. Br J Rheumatol. 1993;32:751–3.
21. Wegrzyn J, Adeleine P, Miossec P., Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63:1232–4.
22. ® CAPSULES 2 mg. Proper use information. Vol. 21. New York, NY: Pfizer Inc.; 2015.
23. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M., Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31:645–8.
24. Korber H, Iven H, Gross WL., Bioavailability and pharmacokinetics of methotrexate (MTX) and its metabolite 7-hydroxy MTX after low dose MTX (25 mg) in patients with chronic rheumatic diseases. Arthritis Rheum. 1992;35(l):S142.
25. Freeman-Narrod M, Gerstley BJ, Engstrom PF, Bomstein RS., Comparison of serum concentrations of methotrexate after various routes of administration. Cancer. 1975;36:1619–24.
26. Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE., Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr. 1987;110:788–92.
27. Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58:73–81.
28. Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549–51.
29. Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M., Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol. 2006;33:481–5.
30. Bianchi G, Caporali R, Todoerti M, Mattana P., Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33:369–78.
31. Singh JA, Saag SK, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology recommendations for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.
32. Rath T, Rubbert A., Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(61):S52–S7.
33. Dale J, Alcorn N, Capell H, Madhok R. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs. Nat Clin Pract Rheumatol. 2007;3:450–8.
34. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995;333:137–41.
35. Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S., Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford). 2003;42:1545–9.
36. Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis. 2007;66:235–41.
37. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220–5.
38. Haagsma CJ, van Riel PL, de Rooij DJ, Vree TB, Russel FJ, van’t Hof MA, et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol.1994;33:1049–55.
39. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol. 1997;36:1082–8.
40. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2002;137:726–33.
41. Lehman AJ, Esdaile JM, Klinkhoff AV, Grant E, Fitzgerald A, Canvin J, et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum. 2005;52:1360–70.
42. Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. 2003;48:2763–8.
43. Kitahama M, Nakajima A, Inoue E, Taniguchi A, Momohara S, Yamanaka H, et al. Efficacy of adjunct tacrolimus treatment in patients with rheumatoid arthritis with inadequate responses to methotrexate. Mod Rheumatol. 2013;23:788–93.
44. Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013;23:430–9.
45. Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2014;24:410–18.
46. Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, et al. Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1069–72.
47. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol. 2005;15:323–8.
48. Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73:516–28.
49. Klareskog L, vander Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–81.
50. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011;38:1585–92.
51. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26–37.
52. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009;60:2272–83.
53. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosisfactor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis. 2009;68:789–96.
54. Jansen JP, Buckley F, Dejonckheere F, Ogale S., Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs—a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12:102.
55. Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP., Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm. 2015;21:409–23.
56. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817–29.
57. Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014;73:803–9.
58. Kaneko Y, Atsumi T, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Ann Rheum Dis. 2016;75:1917–23.
59. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19.
60. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–70.
61. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P., The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis: a metaanalysis of randomized controlled trials. J Rheumatol. 1998;25:36–43.
62. Pincus T., Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis. Clin Exp Rheumatol. 1998;16:667–8.
63. Whittle SL, Hughes RA., Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford). 2004;43:267–71.
64. Morgan SL, Baggott JE., Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(61):S102–S9.
65. Strober BE, Menon K., Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53:652–9.
66. Shea B, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol. 2014;41:1049–60.
67. Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y, et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol. 1999;28:273–81.
68. Tishler M, Caspi D, Fishel B, Yaron M., The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis Rheum. 1988;31:906–9.
69. Joyce DA, Will RK, Hoffman DM, Laing B, Blackboum SJ., Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis. 1991;50:913–14.
70. Köttgen A, Pattaro C, Böger CA, Fuchsberger C, Olden M, Glazer NL, et al. New loci associated with kidney function and chronic kidney disease. Nat Genet. 2010;42:376–84.
71. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44:339–42.
72. Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N., Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:375–6.
73. Oketani M, Ido A, Uto H, Tsubouchi H., Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42:627–36.
74. Watanabe M, Banno S, Sasaki K, Naniwa T, Hayami Y, Ueda R., Serodiagnosis of Mycobacterium avium-complex pulmonary disease with an enzyme immunoassay kit that detects anti-glycopeptidolipid core antigen IgA antibodies in patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:144–9.
75. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol. 1995;22:218–23.
76. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 1996;39:723–31.
77. Kent PD, Luthra HS, Michet C, Jr. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J Rheumatol. 2004;31:1727–31.
78. Cheung PP, Dougados M, Gossec L., Reliability of ultrasonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1,415 patients). Arthritis Care Res. 2010;62:323–34.
79. del Olmo L, Hemández B, Galindo-Izquierdo M, Tébar D, Balsa A, Carmona L., Perioperative management of disease modifying anti-rheumatic drugs: recommendations based on a meta-analysis. Rev Esp Cir Ortop Traumatol. 2012;56:393–412.
80. Loza E, Martinez-Lopez JA, Carmona L., A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol. 2009;27:856–62.
81. Pieringer H, Stuby U, Biesenbach G., The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol. 2008;27:1217–20.
82. Pieringer H, Stuby U, Biesenbach G., Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment? Semin Arthritis Rheum. 2007;36:278–86.
83. Perhala RS, Wilke WS, Clough JD, Segal AM., Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum. 1991;34:146–52.
84. Murata K, Yasuda T, Ito H, Yoshida M, Shimizu M, Nakajima T., Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol. 2006;16:14–19.
85. Sany J, Anaya JM, Canovas F, Combe B, Jorgensen C, Saker S, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol. 1993;20:1129–32.
86. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60:214–17.
87. Bridges SL, Jr, López-Méndez A, Han KH, Tracy IC, Alarcón GS., Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol. 1991;18:984–8.
88. Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE., Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics. 1996;19:207–10.
89. Hyoun SC, Običan SG, Scialli AR., Teratogen update: methotrexate. Birth Defects Res Part A Clin Mol Teratol. 2012;94:187–207.
90. Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795–810.
91. Johns DG, Rutherford LD, Leighton PC, Vogel CL., Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972;112:978–80.
92. Thorne JC, Nadarajah T, Moretti M, Ito S., Methotrexate use in a breastfeeding patient with rheumatoid arthritis. J Rheumatol. 2014;41:2332.
93. Sammaritano LR, Bermas BL., Rheumatoid arthritis medications and lactation. Curr Opin Rheumatol. 2014;26:354–60.
94. Buchbinder R, Hall S, Sambrook PN, Champion GD, Harkness A, Lewis D, et al. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1993;20:639–44.
95. Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR., Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996;39:272–6.
96. Kuitunen T, Maimström J, Palva E, Pettersson T., Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999. Scand J Rheumatol. 2005;34:238–41.
97. Lim AY, Gaffney K, Scott DG., Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology (Oxford). 2005;44:1051–5.
98. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF., The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005;44:61–6.
99. Saravanan V, Kelly CA., Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:143–7.
100. Imokawa S, Colby TV, Leslie KO, Helmers RA., Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J. 2000;15:373–81.
101. Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127:356–64.
102. Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997;24:2299–303.
103. Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51:260–77.
104. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE., Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–300.
105. Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL., Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum. 2012;64:2847–55.
106. Kaiser R., Incidence of lymphoma in patients with rheumatoid arthritis: systematic review of the literature. Clin Lymphoma Myeloma. 2008;8:87–93.
107. Hashimoto A, Chiba N, Tsuno H, Komiya A, Furukawa H, Matsui T, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42:564–71.
108. Yamada T, Nakajima A, Inoue E, Tanaka E, Taniguchi A, Momohara S, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int. 2011;31:1487–92.
109. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S., Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212–21.
110. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.
111. Kameda T, Dobashi H, Miyatake N, Inoo M, Onishi I, Kurata N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2014;66:1302–9.